Pacira BioSciences (PCRX) Other Non-Current Liabilities (2010 - 2026)

Pacira BioSciences' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $24.6 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 3.12% year-over-year to $24.6 million in Q1 2026; TTM through Mar 2026 was $24.6 million, a 3.12% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 22.33% from the prior year.
• Other Non-Current Liabilities rose to $24.6 million in Q1 2026 per PCRX's latest filing, from $20.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $25.3 million in Q3 2025 and bottomed at $9.7 million in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $13.6 million (2023), against an average of $16.6 million.
• Biggest YoY gain for Other Non-Current Liabilities was 153.04% in 2022; the steepest drop was 51.59% in 2022.
• Year by year, Other Non-Current Liabilities stood at $9.7 million in 2022, then jumped by 40.38% to $13.6 million in 2023, then rose by 23.9% to $16.8 million in 2024, then rose by 22.33% to $20.6 million in 2025, then rose by 19.63% to $24.6 million in 2026.
• Per Business Quant, the three latest PCRX Other Non-Current Liabilities figures stand at $24.6 million (Q1 2026), $20.6 million (Q4 2025), and $25.3 million (Q3 2025).